Type 2 diabetes patients who were treated with infusions of Mesoblast's mesenchymal precursor cells had greater reductions in blood sugar levels than those who received a placebo, according to a study presented at a meeting of the American Diabetes Association. The 61-patient midstage trial found that the cells were well-tolerated and that treatment was associated with a dose-dependent improvement in glycemic control.

Related Summaries